News-Papers
Testimonial
Video Gallery
Phosphotyrosine phosphatase SHP-1, somatostatin and prostate cancer
Published on Friday, 18 July 2014
Abstract
We review the mechanisms involved in prostatic growth based on androgens and product of neuroendocrine secretion, with special reference to the role of somatostatin (SS) in the inhibition of neoplastic growth.
Our contributions in the field confirm the antiproliferative effect of SS on the prostate is mediated by phosphotyrosine phosphatase SHP-1, that is present in human prostate.
This enzyme plays a role in the control of prostatic cell proliferation and in the progression of prostate cancer.
Besides, we consider its presence may determine the therapeutic potential of SS in the control of prostate cancer.
Search
Follow us...
Latest
- Therapeutic Potential of Melatonin Counteracting Chemotherapy-Induced Toxicity in Breast Cancer Patients: A Systematic Review
- Somatostatin receptor 2 expression in nasopharyngeal cancer is induced by Epstein Barr virus infection: impact on prognosis, imaging and therapy
- Melatonin: A Potential Regulator of DNA Methylation
- Somatostatin, its receptors and analogs, in lung cancer
- Melatonin in Combination with Albendazole or Albendazole Sulfoxide Produces a Synergistic Cytotoxicity against Malignant Glioma Cells through Autophagy and Apoptosis
- Somatostatin receptor-targeted anti-cancer therapy
- Somatostatin and analogues in the treatment of cancer. A review
- Potential of Melatonin as Adjuvant Therapy of Oral Cancer in the Era of Epigenomics
- Biology of somatostatin in breast cancer
- Melatonin inhibited the progression of gastric cancer induced by Bisphenol S via regulating the estrogen receptor 1
- 1,25-Dihydroxyvitamin D3 induces programmed cell death in a rat glioma cell line
- Prolactin and its receptor as therapeutic targets in glioblastoma multiforme
- Stimulation of prolactin receptor induces STAT-5 phosphorylation and cellular invasion in glioblastoma multiforme
- Vitamin D inhibits osteosarcoma by reprogramming nonsense-mediated RNA decay and SNAI2-mediated epithelial-to-mesenchymal transition
- Melatonin inhibits 17β-estradiol-induced migration, invasion and epithelial-mesenchymal transition in normal and endometriotic endometrial epithelial cells
- Peptide Radioligands in Cancer Theranostics: Agonists and Antagonists
- Osteogenesis from Dental Pulp Derived Stem Cells: A Novel Conditioned Medium Including Melatonin within a Mixture of Hyaluronic, Butyric, and Retinoic Acids
- About melatonin - 1996
Most Read
- The Di Bella Method (DBM)
- All-trans-retinoic acid and cancer
- About melatonin - 1996
- Biography
- The Di Bella Method Increases by the 30% the survival rate for Pancreas tumors and for this reason should be proposed as first line therapy for this type of cancer
- Chronic Lymphocytic Leukemia: 4 patients, long-lasting remission
- Bibliography
- Somatostatin in oncology, the overlooked evidences
- Large B-cells Non-Hodgkin's Lymphoma, Stage IV-AE: a Case Report
- Non-Hodgkin's Lymphoma, Stage III-B-E: a Case Report
- How effective is chemo therapy?
- Vademecum
- Frequently Asked Questions
- Complete objective response to biological therapy of plurifocal breast carcinoma
- Treatment of Low-grade Non-Hodgkin’s Lymphomas at Advanced Stage
- Declaration recommends eliminate the use of Impact factor for research evaluation
- Malignant pleural mesothelioma, stage T3-T4 - Consideration of a case study
- Non–Small-Cell Lung Cancer Patients with Low Performance Status: study on 28 patients